We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vermillion Announces U.S. Patent Office Re-Issues Seldi Mass Spectrometry Patent
News

Vermillion Announces U.S. Patent Office Re-Issues Seldi Mass Spectrometry Patent

Vermillion Announces U.S. Patent Office Re-Issues Seldi Mass Spectrometry Patent
News

Vermillion Announces U.S. Patent Office Re-Issues Seldi Mass Spectrometry Patent

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vermillion Announces U.S. Patent Office Re-Issues Seldi Mass Spectrometry Patent"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vermillion, Inc. has announced that the United States Patent and Trademark Office has issued a Reexamination Certificate of U.S. Patent No. 6,734,022, which is directed to a fundamental process of SELDI mass spectrometry.

As a result of the patent reissuance, Bio-Rad Laboratories is expected to pay Vermillion $2.0 million pursuant to the terms of the Asset Purchase Agreement entered into in connection with the sale of Vermillion's instrumentation business to Bio-Rad on November 13, 2006.

"We believe this patent further validates the innovation underlying SELDI technology and look forward to receiving Bio-Rad's payment," said Gail S. Page, President and Chief Executive Officer of Vermillion. "We continue to make excellent progress translating the SELDI-enabled biomarker discoveries into novel, high-value molecular diagnostic tests."

Advertisement